Latest Trials Latest NewsFAQ

GILEAD SCIENCES SL

🇪🇸Spain

Country: 🇪🇸Spain

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $95.8B

Website: http://www.gilead.com/about/worldwide-operations/europe/spain

Clinical Trials

A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Treatment A
Drug: Treatment D
Drug: Treatment B
Drug: Treatment C
Drug: Treatment E
Drug: Treatment F
Drug: Treatment G
Drug: Treatment H
Drug: Treatment I
Drug: Treatment J

First Posted Date: 2013-04-26

Last Posted Date: 2014-02-07

Lead Sponsor: Gilead Sciences

Target Recruit Count: 56

Registration Number: NCT01841489

Locations: 🇺🇸
Investigational Site, Daytona Beach, Florida, United States

Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CF

Phase 1

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: GS-5737
Drug: Placebo

First Posted Date: 2013-04-26

Last Posted Date: 2014-08-12

Lead Sponsor: Gilead Sciences

Target Recruit Count: 8

Registration Number: NCT01840735

Locations: 🇺🇸
Compass Research Phase 1, LLC, Orlando, Florida, United States

Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection

Phase 3

Completed

Conditions: Hepatitis C Virus

Interventions: Drug: SOF
Drug: RBV

First Posted Date: 2013-04-24

Last Posted Date: 2015-05-22

Lead Sponsor: Gilead Sciences

Target Recruit Count: 103

Registration Number: NCT01838590

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 (Andecaliximab) in Adults With Moderate to Severe Active Ulcerative Colitis

Phase 1

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: Andecaliximab
Drug: Placebo to match Andecaliximab

First Posted Date: 2013-04-15

Last Posted Date: 2021-02-01

Lead Sponsor: Gilead Sciences

Target Recruit Count: 74

Registration Number: NCT01831427

Locations: 🇺🇸
Ehrhardt Clinical Research, LLC, Belton, Missouri, United States
🇺🇸
Delta Research Partners LLC, Monroe, Louisiana, United States
🇷🇴
Institute of Pulmonology "Marius Nasta", Bucharest, Romania

and more 13 locations

Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection

Phase 2

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: SOF
Drug: LDV/SOF
Drug: VEL
Drug: GS-9669
Drug: RBV
Drug: Peg-IFN

First Posted Date: 2013-04-09

Last Posted Date: 2018-11-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 359

Registration Number: NCT01826981

Locations: 🇳🇿
Auckland Clinical Studies Ltd., Auckland, New Zealand
🇳🇿
Christchurch Clinical Studies Trust, Christchurch, New Zealand

Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

Phase 3

Completed

Conditions: HIV
HIV Infections

Interventions: Drug: E/C/F/TAF

First Posted Date: 2013-03-26

Last Posted Date: 2020-03-02

Lead Sponsor: Gilead Sciences

Target Recruit Count: 252

Registration Number: NCT01818596

Locations: 🇺🇸
Peter J Ruane, MD, Inc, Los Angeles, California, United States
🇺🇸
Mercer University, Macon, Georgia, United States
🇺🇸
Anthony Mills MD, Inc, Los Angeles, California, United States

and more 67 locations

A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

Phase 1

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: GS-5816

First Posted Date: 2013-03-26

Last Posted Date: 2013-08-29

Lead Sponsor: Gilead Sciences

Target Recruit Count: 33

Registration Number: NCT01817985

Locations: 🇵🇷
Investigational Site, San Juan, Puerto Rico

Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

Phase 3

Completed

Conditions: HIV
HIV Infections

Interventions: Drug: E/C/F/TDF
Drug: E/C/F/TAF
Drug: EFV/FTC/TDF
Drug: RTV
Drug: ATV
Drug: FTC/TDF
Drug: COBI

First Posted Date: 2013-03-21

Last Posted Date: 2021-04-13

Lead Sponsor: Gilead Sciences

Target Recruit Count: 1443

Registration Number: NCT01815736

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Southwest Infectious Disease Clinical Research, Inc., Dallas, Texas, United States
🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

and more 164 locations

Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3

Phase 2

Completed

Conditions: Hepatitis C

Interventions: Drug: SOF
Drug: PEG
Drug: RBV

First Posted Date: 2013-03-11

Last Posted Date: 2014-09-12

Lead Sponsor: Gilead Sciences

Target Recruit Count: 47

Registration Number: NCT01808248

Locations: 🇺🇸
Alamo Medical Research, San Antonio, Texas, United States

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors

Phase 1

Completed

Conditions: Pancreatic Cancer
Esophagogastric Cancer
Non-small Cell Lung Cancer
Breast Cancer
Colorectal Cancer

Interventions: Drug: Andecaliximab
Drug: Gemcitabine
Drug: Carboplatin
Drug: Leucovorin
Drug: Nab-paclitaxel
Drug: Pemetrexed
Drug: Paclitaxel
Drug: Oxaliplatin
Drug: 5-FU
Drug: Bevacizumab
Drug: Irinotecan

First Posted Date: 2013-03-04

Last Posted Date: 2020-06-02

Lead Sponsor: Gilead Sciences

Target Recruit Count: 236

Registration Number: NCT01803282

Locations: 🇺🇸
Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸
University of Southern California (USC), Los Angeles, California, United States
🇺🇸
Parkview Research Center, Fort Wayne, Indiana, United States

and more 15 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy